Navigation Links
Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22

Irvine, CA - (PRWEB) November 18, 2013

Proove Biosciences, the leading personalized pain medicine laboratory, will be exhibiting and presenting clinical data and research at the National Workers’ Compensation and Disability Conference Expo. This industry-leading event attracts thousands of workers’ compensation and disability management professionals from around the country, and will be hosted at the Mandalay Bay Hotel, in Las Vegas November 20-22, 2013.

The NWCD Conference allows professionals to receive guidance and insight on new trends from experts spanning all spectrum of the industry. This year’s event will contain a brand new track on disability management solutions, sessions devoted to critical issues in trendsetting states which typically affect associated regions, and an emphasis on technology, innovation and research.

Proove Biosciences has been presenting research and findings at pain medicine scientific meetings across the country in 2013, and will now have the opportunity to present to the case managers, claims managers, health and safety professionals, legislators, and other workers compensation and disability claims personnel in attendance. This year’s emphasis on technology and innovation aligns perfectly with Proove’s mission and capacity in delivering scientific proof towards reducing costs and improving outcomes of workers compensation claims.

“Workers compensation and disability claims are a huge cost driver in this industry, in larger part because of medical abuse and dependence that stems from a gap in understanding a patient's individual genetic profile,” stated Proove Biosciences President and Founder, Brian Meshkin. “We are the only company providing proprietary testing services in personalized pain medicine, and the only company with data specifically on genetics and pain medicine. We are happy and excited to exhibit our work at the NWCD and help inform professionals on how we can all lower risk, costs, and improve patient and worker health.”

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
2. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
3. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
4. Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree
5. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
6. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
9. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
10. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... software integration with MarkLogic, the Enterprise NoSQL database platform provider, creating a ... change. , Smartlogic’s Content Intelligence capabilities provide a robust set of semantic ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, ... spectroscopy, covers a wide range of applications such as, but not limited to, ...
(Date:11/25/2015)... , November 26, 2015 ... Global Biobanking Market 2016 - 2020 report analyzes ... maintaining integrity and quality in long-term samples, minimizing ... long-term cost-effectiveness. Automation minimizes manual errors such as ... technical efficiency. Further, it plays a vital role ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
Breaking Biology News(10 mins):